NUVL

Nuvalent, Inc.

Nasdaq · Pharmaceutical Preparations · Inc. DE · CIK 0001861560

$123.25 -0.16% $9.7B

Insider Selling Cluster (4 insiders)High Impact Filing (8/10)17 New Institutional Positions3 Institutional Exits

Vol

Market Cap$9.7B

Cap SizeMid Cap

Analyst ConsensusStrong Buy (96%)

Inst. Holders50 funds

Inst. Value$3.9B

Inst. Activity17 buys / 3 sells

Insider Activity0B / 19S

Insider Net $-$12.8M

SEC Reports13

Exchange Nasdaq·Sector Pharmaceutical Preparations·Inc. DE·CIK 0001861560·Prev Close $123.45

Recent Activity

Jun 11, 2026 SEC

Two Nuvalent insiders (CEO and Chief Development Officer) sold a combined ~$3.56M in open-market shares on June 8-9, 202

CLUSTER — Impact 2/10

Jun 10, 2026 SEC

Nuvalent CEO James Porter exercised 30,000 options at $18.93/share and sold 12,495 shares on the open market for $1.1M,

CLUSTER — Impact 3/10

Jun 9, 2026 SEC

GSK plc has agreed to acquire Nuvalent for $124.00 per share in cash, representing a total equity value of $10.6 billion

8-K — Impact 8/10

Jun 9, 2026 Insider

Noci Darlene acquired via exercise 10,000 shares

Chief Development Officer @ $1.08 ($10.8K)

Jun 9, 2026 Insider

Noci Darlene sold 20,000 shares

Chief Development Officer @ $122.81 ($2.5M)

Jun 8, 2026 Insider

Porter James Richard acquired via exercise 30,000 shares

President and CEO @ $18.93 ($567.9K)

Inst.

RA CAPITAL MANAGEMENT, L.P. — ADD

2,534,145 shares ($259.6M)

Inst.

FRONTIER CAPITAL MANAGEMENT CO — ADD

395,546 shares ($40.5M)

Price Targets

$128.13 +4.0% upside Hold

Current $123.25 Low $124.00 Median $124.00 High $172.00 16 analysts

$124.00 $172.00

Analyst Ratings

Strong Buy96% buy · 24 analysts

7Strong Buy

16Buy

1Hold

0Sell

0Strong Sell

Recent Analyst Actions

Date	Firm	Action	Rating
Jun 10, 2026	TD Cowen	DOWNGRADE	Buy → Hold
Jun 10, 2026	Barclays	DOWNGRADE	Overweight → Equal-Weight
Jun 10, 2026	Wedbush	DOWNGRADE	Outperform → Neutral
Jun 10, 2026	UBS	DOWNGRADE	Buy → Neutral
Jun 10, 2026	Guggenheim	DOWNGRADE	Buy → Neutral

Earnings Estimates

Period	EPS Est.	Range	Growth	#
Current Q	$-1.37 ▲ +1.1%	$-1.48 — $-1.13	2% YoY	15
Next Q	$-1.39 ▲ +0.7%	$-1.57 — $-1.21	18% YoY	15
Current FY	$-5.48	$-6.37 — $-4.66	6% YoY	16
Next FY	$-4.13	$-6.83 — $-1.06	25% YoY	16

Latest Reports

NEUTRAL CLUSTER 2/10

Two Nuvalent insiders (CEO and Chief Development Officer) sold a combined ~$3.56M in open-market shares on June 8-9, 202

Jun 11, 2026

NEUTRAL CLUSTER 3/10

Nuvalent CEO James Porter exercised 30,000 options at $18.93/share and sold 12,495 shares on the open market for $1.1M,

Jun 10, 2026

Top Institutional Holders

Fund	Value	Move
NOMURA ASSET MANAGEMENT CO	—	—
FMR LLC	$950.2M	—
BlackRock, Inc.	$494.3M	—
RA CAPITAL MANAGEMENT, L.P.	$259.6M	ADD
VANGUARD PORTFOLIO MANAGEMENT LLC	$256.2M	—

Recent Insider Trades

Date	Insider	Type	Value
Jun 9, 2026	Noci Darlene	M	$10.8K
Jun 9, 2026	Noci Darlene	SELL	$2.5M
Jun 8, 2026	Porter James	M	$567.9K
Jun 8, 2026	Porter James	SELL	$1.1M
Jun 1, 2026	Balcom Alexandra	M	$78.8K

50 institutional holders with $3.9B total value (38,154,866 shares) as of 2026-Q1. Top holders: NOMURA, FMR, BlackRock,. Net buying activity: 17 institutions added/increased vs 3 reduced.

Top Institutional Holders — 2026-Q1

#	Fund	Shares	Value	% of Tracked	Last Move
1	NOMURA ASSET MANAGEMENT CO LTD	—	$0.00	0.0%	—
2	FMR LLC	9,274,959	$950.2M	24.3%	—
3	BlackRock, Inc.	4,824,785	$494.3M	12.7%	—
4	RA CAPITAL MANAGEMENT, L.P.	2,534,145	$259.6M	6.6%	ADD +34.8%
5	VANGUARD PORTFOLIO MANAGEMENT LLC	2,500,907	$256.2M	6.6%	—
6	WELLINGTON MANAGEMENT GROUP LLP	2,470,491	$253.1M	6.5%	ADD +46.0%
7	VANGUARD CAPITAL MANAGEMENT LLC	2,428,488	$248.8M	6.4%	—
8	STATE STREET CORP	2,035,831	$208.6M	5.3%	—
9	Polar Capital Holdings Plc	1,831,253	$187.6M	4.8%	ADD +50.3%
10	JANUS HENDERSON GROUP PLC	1,237,779	$126.8M	3.2%	TRIM -31.5%
11	ALLIANCEBERNSTEIN L.P.	784,023	$78.9M	2.0%	NEW
12	ADAGE CAPITAL PARTNERS GP, L.L.C.	748,896	$76.7M	2.0%	—
13	Woodline Partners LP	610,459	$62.5M	1.6%	TRIM -42.9%
14	AMERIPRISE FINANCIAL INC	563,768	$57.8M	1.5%	—
15	GOLDMAN SACHS GROUP INC	537,158	$55.0M	1.4%	—
16	DRIEHAUS CAPITAL MANAGEMENT LLC	481,180	$49.3M	1.3%	DOUBLED +123.3%
17	Hood River Capital Management LLC	479,998	$49.2M	1.3%	NEW
18	CHARLES SCHWAB INVESTMENT MANAGEMENT INC	450,801	$46.2M	1.2%	—
19	FRANKLIN RESOURCES INC	434,742	$44.5M	1.1%	DOUBLED +156.9%
20	Pictet Asset Management Holding SA	410,485	$42.1M	1.1%	TRIM -34.8%

Recent Position Changes

Fund	Action	Prev Shares	Curr Shares	Change %	Value	Quarter
RA CAPITAL MANAGEMENT, L.P.	ADD	1,880,057	2,534,145	+34.8%	$259.6M	2026-Q1
FRONTIER CAPITAL MANAGEMENT CO LLC	ADD	270,470	395,546	+46.2%	$40.5M	2026-Q1
BNP Paribas Asset Management Holding S.A.	ADD	61,130	81,775	+33.8%	$8.4M	2026-Q1
FIRST TRUST ADVISORS LP	DOUBLED	22,165	47,617	+114.8%	$4.9M	2026-Q1
SEI INVESTMENTS CO	ADD	23,160	29,540	+27.5%	$3.0M	2026-Q1
DIMENSIONAL FUND ADVISORS LP	ADD	10,406	18,893	+81.6%	$1.9M	2026-Q1
ENVESTNET ASSET MANAGEMENT INC	DOUBLED	5,226	15,810	+202.5%	$1.6M	2026-Q1
POLEN CAPITAL MANAGEMENT LLC	DOUBLED	6,359	12,744	+100.4%	$1.3M	2026-Q1
LOS ANGELES CAPITAL MANAGEMENT LLC	DOUBLED	204	9,939	+4772.1%	$1.0M	2026-Q1
PRUDENTIAL FINANCIAL INC	DOUBLED	3,060	7,855	+156.7%	$804.7K	2026-Q1
Vanguard Personalized Indexing Management, LLC	ADD	4,771	7,145	+49.8%	$732.0K	2026-Q1
Brevan Howard Capital Management LP	DOUBLED	2,803	6,384	+127.8%	$654.0K	2026-Q1
MARSHALL WACE, LLP	NEAR_EXIT	23,930	3,194	-86.7%	$327.2K	2026-Q1
PNC FINANCIAL SERVICES GROUP, INC.	ADD	1,678	2,110	+25.7%	$216.2K	2026-Q1
Mitsubishi UFJ Asset Management Co., Ltd.	DOUBLED	70	470	+571.4%	$48.2K	2026-Q1
Rockefeller Capital Management L.P.	DOUBLED	65	336	+416.9%	$34.4K	2026-Q1
Allworth Financial LP	DOUBLED	94	287	+205.3%	$29.4K	2026-Q1
ASSETMARK, INC	ADD	35	57	+62.9%	$5.8K	2026-Q1
BAKER BROS. ADVISORS LP	EXIT	143,937	0	-100.0%	$0.00	2026-Q1
NORGES BANK	EXIT	574,242	0	-100.0%	$0.00	2026-Q1
RA CAPITAL MANAGEMENT, L.P.	ADD	1,246,456	1,880,057	+50.8%	$189.1M	2025-Q4
Polar Capital Holdings Plc	ADD	1,022,225	1,536,859	+50.3%	$154.6M	2025-Q4
JANUS HENDERSON GROUP PLC	TRIM	2,188,674	1,499,574	-31.5%	$150.8M	2025-Q4
ALLIANCEBERNSTEIN L.P.	NEW	—	785,445	—	$79.0M	2025-Q4
Woodline Partners LP	TRIM	1,069,520	610,459	-42.9%	$61.4M	2025-Q4

6 unique insiders with 40 transactions. Net insider value: -$12.8M ($0.00 bought, $12.8M sold).

Insider Transactions

Date	Insider	Title	Type	Shares	Price	Value
Jun 9, 2026	Noci Darlene	Chief Development Officer	EXERCISE	10,000	$1.08	$10.8K
Jun 9, 2026	Noci Darlene	Chief Development Officer	SELL	20,000	$122.81	$2.5M
Jun 8, 2026	Porter James Richard	President and CEO	EXERCISE	30,000	$18.93	$567.9K
Jun 8, 2026	Porter James Richard	President and CEO	SELL	12,495	$87.97	$1.1M
Jun 1, 2026	Balcom Alexandra	Chief Financial Officer	EXERCISE	11,430	$6.89	$78.8K
Jun 1, 2026	Balcom Alexandra	Chief Financial Officer	SELL	960	$94.87	$91.1K
May 28, 2026	Miller Deborah Ann	Chief Legal Officer	SELL	1,401	$106.32	$149.0K
May 28, 2026	Miller Deborah Ann	Chief Legal Officer	EXERCISE	5,500	$6.89	$37.9K
May 4, 2026	Porter James Richard	President and CEO	SELL	1,699	$98.54	$167.4K
May 4, 2026	Porter James Richard	President and CEO	EXERCISE	30,000	$18.93	$567.9K
May 1, 2026	Balcom Alexandra	Chief Financial Officer	EXERCISE	7,159	$1.08	$7.7K
May 1, 2026	Balcom Alexandra	Chief Financial Officer	SELL	3,872	$98.42	$381.1K
Apr 30, 2026	Miller Deborah Ann	Chief Legal Officer	EXERCISE	5,500	$6.89	$37.9K
Apr 30, 2026	Miller Deborah Ann	Chief Legal Officer	SELL	4,418	$99.13	$438.0K
Apr 29, 2026	Noci Darlene	Chief Development Officer	EXERCISE	5,500	$27.85	$153.2K
Apr 29, 2026	Noci Darlene	Chief Development Officer	SELL	4,500	$99.35	$447.1K
Apr 9, 2026	Pelish Henry E.	Chief Scientific Officer	EXERCISE	3,093	$27.85	$86.1K
Apr 9, 2026	Pelish Henry E.	Chief Scientific Officer	SELL	2,193	$104.27	$228.7K
Apr 6, 2026	Porter James Richard	President and CEO	EXERCISE	13,714	$18.93	$259.6K
Apr 6, 2026	Porter James Richard	President and CEO	SELL	11,354	$103.21	$1.2M
Apr 1, 2026	Lane Benjamin	See Remarks	AWARD	9,500	—	—
Apr 1, 2026	Lane Benjamin	See Remarks	AWARD	19,000	—	—
Apr 1, 2026	Balcom Alexandra	Chief Financial Officer	EXERCISE	11,430	$1.08	$12.3K
Apr 1, 2026	Balcom Alexandra	Chief Financial Officer	SELL	3,544	$104.39	$370.0K
Mar 30, 2026	Noci Darlene	Chief Development Officer	EXERCISE	5,500	$27.85	$153.2K
Mar 30, 2026	Noci Darlene	Chief Development Officer	SELL	2,532	$97.43	$246.7K
Mar 26, 2026	Miller Deborah Ann	Chief Legal Officer	EXERCISE	5,500	$6.89	$37.9K
Mar 26, 2026	Miller Deborah Ann	Chief Legal Officer	SELL	940	$97.50	$91.7K
Mar 25, 2026	Balcom Alexandra	Chief Financial Officer	SELL	13,700	$100.16	$1.4M
Mar 24, 2026	Balcom Alexandra	Chief Financial Officer	EXERCISE	11,430	$1.08	$12.3K
Mar 24, 2026	Balcom Alexandra	Chief Financial Officer	SELL	2,599	$95.03	$247.0K
Mar 13, 2026	Pelish Henry E.	Chief Scientific Officer	SELL	804	$97.89	$78.7K
Mar 12, 2026	Pelish Henry E.	Chief Scientific Officer	SELL	24,189	$97.79	$2.4M
Mar 12, 2026	Pelish Henry E.	Chief Scientific Officer	EXERCISE	8,456	$18.93	$160.1K
Mar 6, 2026	Porter James Richard	President and CEO	EXERCISE	30,000	$27.85	$835.5K
Mar 6, 2026	Porter James Richard	President and CEO	SELL	13,585	$98.59	$1.3M
Feb 26, 2026	Noci Darlene	Chief Development Officer	EXERCISE	5,500	$27.85	$153.2K
Feb 26, 2026	Miller Deborah Ann	Chief Legal Officer	EXERCISE	5,500	$6.89	$37.9K
Jan 29, 2026	Noci Darlene	Chief Development Officer	SELL	189	$100.95	$19.1K
Jan 29, 2026	Noci Darlene	Chief Development Officer	EXERCISE	5,500	$27.85	$153.2K

13 SEC filing reports analyzed. Sentiment: 3 bullish, 4 bearish, 0 mixed, 6 neutral. Avg impact: 5.1/10.

NEUTRAL CLUSTER 2/10

Two Nuvalent insiders (CEO and Chief Development Officer) sold a combined ~$3.56M in open-market sha

Jun 11, 2026

NEUTRAL CLUSTER 3/10

Nuvalent CEO James Porter exercised 30,000 options at $18.93/share and sold 12,495 shares on the ope

Jun 10, 2026

BULLISH 8-K 8/10

GSK plc has agreed to acquire Nuvalent for $124.00 per share in cash, representing a total equity va

Jun 9, 2026

NEUTRAL 8-K 4/10

Nuvalent reported Q1 2026 results with a net loss of $109.3M ($1.39/share), wider than the $84.6M lo

May 7, 2026

NEUTRAL CLUSTER 2/10

Three Nuvalent insiders (CFO, CLO, CDO) sold a total of ~$1.27M in open-market shares over three day

May 5, 2026

BEARISH CLUSTER 6/10

Nuvalent CEO and Chief Scientific Officer sold shares worth $1.4M in the past week, including a $1.1

Apr 13, 2026

BEARISH CLUSTER 7/10

Nuvalent CEO and CFO sold shares worth $1.79M in a coordinated cluster over the past week, with the

Apr 8, 2026

BULLISH 8-K 7/10

Nuvalent, Inc. announced the submission of its New Drug Application (NDA) to the U.S. FDA for nelada

Apr 7, 2026

NEUTRAL CLUSTER 3/10

Three Nuvalent executives, including the CFO and Chief Development Officer, sold shares in a coordin

Apr 3, 2026

BEARISH CLUSTER 7/10

Three C-suite executives at Nuvalent sold a combined $1.71M in shares over a 7-day period, including

Apr 1, 2026

BEARISH CLUSTER 6/10

Analysis based on filing metadata only — document content was unavailable. Cross-filing context reve

Mar 30, 2026

NEUTRAL CLUSTER 4/10

Nuvalent's Chief Scientific Officer, Henry E. Pelish, sold 24,993 shares in open-market transactions

Mar 16, 2026

BULLISH 8-K 7/10

Nuvalent reported its 2025 financial results, highlighted a strong cash position of $1.4 billion wit

Feb 26, 2026

∅

No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.

Current analyst consensus: Strong Buy (96% buy). Based on 24 analysts: 7 strong buy, 16 buy, 1 hold, 0 sell, 0 strong sell.

Analyst Price Targets

$128.13 mean target +4.0% upside Hold (2.88)

$124.00 Low $172.00 High

Metric	Value
Current Price	$123.25
Target Low	$124.00
Target Mean	$128.13
Target Median	$124.00
Target High	$172.00
# Analysts	16
Recommendation	Hold (2.88)

Earnings Estimates & Revisions

Period	EPS Avg	EPS Low	EPS High	EPS Growth	30d Rev.	Up/Down	Rev. Avg	Rev. Growth	Analysts
Current Q 2026-06-30	$-1.37	$-1.48	$-1.13	1.6%	+1.1%	6↑ 6↓	$0.0B	0.0%	15
Next Q 2026-09-30	$-1.39	$-1.57	$-1.21	18.4%	+0.7%	6↑ 6↓	$0.0B	0.0%	15
Current FY 2026-12-31	$-5.48	$-6.37	$-4.66	6.4%	-0.3%	7↑ 7↓	$0.0B	0.0%	16
Next FY 2027-12-31	$-4.13	$-6.83	$-1.06	24.5%	-0.0%	8↑ 7↓	$0.2B	1575.4%	16

Current Quarter EPS Revision History

Timepoint	EPS Estimate	Change
Current	$-1.368
7d ago	$-1.378	+0.010
30d ago	$-1.384	+0.015
60d ago	$-1.372	+0.003
90d ago	$-1.373	+0.005

11 analyst firms have rated this stock: 0 upgrades, 10 downgrades, 2 initiations.

Individual Analyst Actions

Date	Analyst Firm	Action	Previous Rating	New Rating
Jun 10, 2026	TD Cowen	DOWNGRADE	Buy	Hold
Jun 10, 2026	Barclays	DOWNGRADE	Overweight	Equal-Weight
Jun 10, 2026	Wedbush	DOWNGRADE	Outperform	Neutral
Jun 10, 2026	UBS	DOWNGRADE	Buy	Neutral
Jun 10, 2026	Guggenheim	DOWNGRADE	Buy	Neutral
Jun 9, 2026	Wells Fargo	DOWNGRADE	Overweight	Equal-Weight
Jun 9, 2026	HC Wainwright & Co.	DOWNGRADE	Buy	Neutral
Jun 9, 2026	Cantor Fitzgerald	DOWNGRADE	Overweight	Neutral
Jun 9, 2026	Wedbush	DOWNGRADE	Outperform	Neutral
Jun 9, 2026	LifeSci Capital	DOWNGRADE	Outperform	Market Perform
May 28, 2026	Wedbush	REITERATE	Outperform	Outperform
May 22, 2026	Bernstein	INITIATE	—	Outperform
Apr 21, 2026	HC Wainwright & Co.	REITERATE	Buy	Buy
Apr 8, 2026	Wedbush	REITERATE	Outperform	Outperform
Mar 30, 2026	Wells Fargo	INITIATE	—	Overweight
Feb 27, 2026	Cantor Fitzgerald	MAINTAIN	Overweight	Overweight
Dec 19, 2025	JP Morgan	MAINTAIN	Overweight	Overweight

Monthly Consensus History

Period	Strong Buy	Buy	Hold	Buy %
Jun 1, 2026	7	16	1	96%
May 1, 2026	8	16	1	96%
Apr 1, 2026	8	15	1	96%
Mar 1, 2026	8	15	1	96%
Feb 1, 2026	8	15	1	96%
Jan 1, 2026	8	15	1	96%

Strong BuyBuyHoldSellStrong Sell

∅

No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.

∅

No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.

Sep 18, 2026

fda_pdufa

PDUFA: NUVL — zidesamtinib in TKI pre-treated advanced ROS1-positive NSCLC — 2026-09-18

FDA target action date 2026-09-18 for NUVL (Nuvalent, Inc.). Drug: zidesamtinib. Indication: TKI pre-treated advanced ROS1-positive NSCLC. FDA assigne

Jun 3, 2026

short_volume

Short Volume: NUVL — 62.5% short (0.5M / 0.7M)

Short: 452,595 | Exempt: 220 | TRF Vol: 724,386 | Short Ratio: 62.5% | Off-exchange volume (dark pool + OTC)

Jun 2, 2026

short_volume

Short Volume: NUVL — 74.7% short (0.6M / 0.8M)

Short: 602,119 | Exempt: 7,817 | TRF Vol: 806,093 | Short Ratio: 74.7% | Off-exchange volume (dark pool + OTC)

Jun 1, 2026

short_volume

Short Volume: NUVL — 66.2% short (1.0M / 1.5M)

Short: 986,800 | Exempt: 5,095 | TRF Vol: 1,490,072 | Short Ratio: 66.2% | Off-exchange volume (dark pool + OTC)

May 7, 2026

earnings_calendar

NUVL Q1 2026 Earnings Scheduled — 2026-05-07

May 6, 2026

earnings_calendar

NUVL Q1 2026 Earnings Scheduled — 2026-05-06

Mar 4, 2026

earnings_calendar

NUVL Q4 2025 Earnings After Market Close — 2026-03-04

Feb 4, 2026

short_interest

FTD: NUVL — 7,149 shares ($0.8M) failed to deliver

Settlement: 20260204, Price: $107.17, FTD Value: $766,158.33, NUVALENT INC CL A (DE)

Feb 2, 2026

short_interest

FTD: NUVL — 5,588 shares ($0.6M) failed to deliver

Settlement: 20260202, Price: $102.89, FTD Value: $574,949.32, NUVALENT INC CL A (DE)